V. Filiaci

发表

Clinical trial designs for rare diseases: Studies developed and discussed by the International Rare Cancers Initiative

J. Blay, M. Sydes, A. Benson, 2015, European journal of cancer.

A randomized phase III trial of cisplatin and tumor volume directed irradiation followed by carboplatin and paclitaxel vs. carboplatin and paclitaxel for optimally debulked, advanced endometrial carcinoma.

D. Matei, D. Mutch, D. Miller, 2017 .

Patient reported outcomes for cisplatin and radiation followed by carboplatin/paclitaxel versus carboplatin/paclitaxel for locally advanced endometrial carcinoma: An NRG oncology study.

W. E. Richards, D. Matei, D. Mutch, 2021, Gynecologic oncology.

Adjuvant Chemotherapy plus Radiation for Locally Advanced Endometrial Cancer.

W. E. Richards, D. Matei, W. Small, 2019, The New England journal of medicine.

Disparities in health-related quality of life in women undergoing treatment for advanced ovarian cancer: the role of individual-level and contextual social determinants

L. Minasian, S. Temkin, J. Moss, 2018, Supportive Care in Cancer.

TP53 Sequencing and p53 Immunohistochemistry Predict Outcomes When Bevacizumab Is Added to Frontline Chemotherapy in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study

K. Thiel, E. Devor, K. Leslie, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: a Gynecologic Oncology Group study.

R. Mannel, N. Susumu, P. Rose, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Surgical Window Trial Evaluating Medroxyprogesterone Acetate with or without Entinostat in Patients with Endometrial Cancer and Validation of Biomarkers of Cellular Response

Richard G. Moore, E. Kohn, E. Hill, 2021, Clinical Cancer Research.

An international randomized phase III trial of pulse actinomycin-D versus multi-day methotrexate for the treatment of low risk gestational trophoblastic neoplasia; NRG/GOG 275

N. Horowitz, D. Miller, K. Moxley, 2020, Gynecologic oncology.

Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study.

D. Provencher, R. Mannel, J. Kelley, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Late-Breaking Abstract 1: Randomized phase III noninferiority trial of first line chemotherapy for metastatic or recurrent endometrial carcinoma: A Gynecologic Oncology Group study

D. Miller, Takashi Matsumoto, G. Fleming, 2012 .

GOG 3007, a randomized phase II (RP2) trial of everolimus and letrozole (EL) or hormonal therapy (medroxyprogesterone acetate/tamoxifen, PT) in women with advanced, persistent or recurrent endometrial carcinoma (EC): A GOG Foundation study

D. Miller, R. Coleman, Joan L. Walker, 2018, Gynecologic Oncology.

Randomized Phase III Trial of Paclitaxel and Carboplatin Versus Paclitaxel and Ifosfamide in Patients With Carcinosarcoma of the Uterus or Ovary: An NRG Oncology Trial

D. Mutch, A. Secord, D. Miller, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

1A randomized phase III trial of pelvic radiation therapy (PXRT) versus vaginal cuff brachytherapy followed by paclitaxel/carboplatin chemotherapy (VCB/C) in patients with high risk (HR), early stage endometrial cancer (EC): A Gynecologic Oncology Group trial

J. W. Kim, T. Rutherford, C. Aghajanian, 2014 .

Effects of Slide Storage on Detection of Molecular Markers by IHC and FISH in Endometrial Cancer Tissues From a Clinical Trial: An NRG Oncology/GOG Pilot Study

O. Olopade, A. Montag, M. Birrer, 2021, Applied immunohistochemistry & molecular morphology : AIMM.

Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study.

J. Thigpen, R. Mannel, H. Muss, 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Second Curettage for Low-Risk Nonmetastatic Gestational Trophoblastic Neoplasia

J. Chan, D. Miller, K. Behbakht, 2016, Obstetrics and gynecology.

Mutated p53 portends improvement in outcomes when bevacizumab is combined with chemotherapy in advanced/recurrent endometrial cancer: An NRG Oncology study.

D. Levine, D. Mutch, A. Secord, 2021, Gynecologic oncology.

A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: A GOG Foundation study.

C. Muller, D. Miller, R. Coleman, 2022, Gynecologic oncology.

Tumor mutational analysis of GOG248, a phase II study of temsirolimus or temsirolimus and alternating megestrol acetate and tamoxifen for advanced endometrial cancer (EC): An NRG Oncology/Gynecologic Oncology Group study.

M. Birrer, K. Behbakht, Yuping Zhang, 2015, Gynecologic oncology.

Temsirolimus with or without megestrol acetate and tamoxifen for endometrial cancer: a gynecologic oncology group study.

K. Leslie, G. Fleming, R. Zaino, 2014, Gynecologic oncology.

Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209).

D. Cella, D. Miller, Takashi Matsumoto, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase III trial of ifosfamide with or without paclitaxel in advanced uterine carcinosarcoma: a Gynecologic Oncology Group Study.

B. Monk, P. Bitterman, M. Markman, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

An exploratory analysis of HER-2 amplification and overexpression in advanced endometrial carcinoma: a Gynecologic Oncology Group study.

O. Olopade, A. Mundt, Karin K Ridderstråle, 2008, Gynecologic oncology.

Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study.

R. Bentley, G. Fleming, J. Sorosky, 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase II study of frontline paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus, or ixabepilone/carboplatin/bevacizumab in advanced/recurrent endometrial cancer.

A. Stuckey, Jianjiong Gao, D. Levine, 2018, Gynecologic oncology.

A randomized phase II study of paclitaxel/carboplatin/bevacizumab, paclitaxel/carboplatin/temsirolimus and ixabepilone/carboplatin/bevacizumab as initial therapy for measurable stage III or IVA, stage IVB or recurrent endometrial cancer, GOG-86P.

A. Stuckey, D. Levine, A. Secord, 2015 .

Phase III Trial: Adjuvant Pelvic Radiation Therapy Versus Vaginal Brachytherapy Plus Paclitaxel/Carboplatin in High-Intermediate and High-Risk Early Stage Endometrial Cancer.

Jae-Weon Kim, W. Small, D. Miller, 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 3 Trial of Pelvic Radiation Therapy Versus Vaginal Cuff Brachytherapy Followed by Paclitaxel/Carboplatin Chemotherapy in Patients with High-Risk, Early-Stage Endometrial Cancer: A Gynecology Oncology Group Study

W. Small, D. Miller, C. Yashar, 2017 .

The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.

G. Fleming, J. Thigpen, H. Gallion, 2007, Gynecologic oncology.

Association of number of positive nodes and cervical stroma invasion with outcome of advanced endometrial cancer treated with chemotherapy or whole abdominal irradiation: a Gynecologic Oncology Group study.

B. Monk, J. Thigpen, R. Mannel, 2012, Gynecologic oncology.

Phase II evaluation of dalantercept, a soluble recombinant activin receptor-like kinase 1 (ALK1) receptor fusion protein, for the treatment of recurrent or persistent endometrial cancer: an NRG Oncology/Gynecologic Oncology Group Study 0229N.

C. Aghajanian, G. Sutton, K. Moxley, 2015, Gynecologic oncology.

A randomized phase 3 trial of paclitaxel (P) plus carboplatin (C) versus paclitaxel plus ifosfamide (I) in chemotherapy-naive patients with stage I-IV, persistent or recurrent carcinosarcoma of the uterus or ovary: An NRG Oncology trial.

W. Richards, D. Mutch, A. Secord, 2019, Journal of Clinical Oncology.

High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study.

J. Miecznikowski, J. Gonzalez-Bosquet, M. Birrer, 2017, Gynecologic oncology.

Hormone therapy plus temsirolimus for endometrial carcinoma (EC): Gynecologic Oncology Group trial #248.

K. Leslie, G. Fleming, R. Zaino, 2011, Journal of Clinical Oncology.

Evaluation of slide storage and detection of molecular markers by immunohistochemistry (IHC) in formalin-fixed, paraffin embedded endometrial cancer tissues from a clinical trial: A GOG study

O. Olopade, A. Montag, M. Birrer, 2014 .

Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol.

D. Mutch, S. Waggoner, J. Boggess, 2017, Gynecologic Oncology.

Synuclein‐γ in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study

D. Scholtens, Meenakshi Singh, N. Ramirez, 2017, Cancer.

Evidence for synthetic lethality between bevacizumab and chemotherapy in advanced, p53 null endometrial cancers

A. Stuckey, D. Levine, A. Secord, 2018, Gynecologic Oncology.

A phase II evaluation of paclitaxel and carboplatin in the treatment of carcinosarcoma of the uterus: A Gynecologic Oncology Group (GOG) study.

R. Mannel, N. Susumu, P. Rose, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.